(UroToday.com) In this presentation, Dr. Michael Morris presented the results of the phase 3 VISION trial evaluating the radiopharmaceutical lutetium-PSMA (Lu-PSMA) in patients with metastatic ...
(UroToday.com) The 2025 ESMO annual meeting featured a urothelial carcinoma trials in progress session and a presentation by Dr. Petros Grivas discussing INTerpath-011, a phase 2 study of intismeran ...
(UroToday.com) The 2025 ESMO annual meeting featured a prostate cancer session and a presentation by Dr. Shun Zhang discussing a phase 1 study of QLH12016, an androgen receptor PROTAC degrader in ...
(UroToday.com) The 2024 European Society for Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain between September 13 th and 16 th, 2024 was host to a session on future therapy targets ...
(UroToday.com) The 2025 SUO annual meeting featured a urothelial carcinoma trials in progress session and a presentation by Dr. Eugene Pietzak discussing the GAIN trial assessing gemcitabine ...
(UroToday.com) The 2025 ESMO annual meeting featured a testis cancer session and a presentation by Dr. Axel Heidenreich discussing the final results of the COTRIMS (COlogne Trial of Retroperitoneal ...
(UroToday.com) The 2025 ESMO annual meeting featured a Presidential Symposium session and a presentation by Dr. Thomas B. Powles discussing results from IMvigor011, a phase 3 trial of ctDNA-guided ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results